top of page
Search

Prof. dr. Nicole Blijlevens joins Akthelia's Scientific Advisory Board

  • Writer: Akthelia News Desk
    Akthelia News Desk
  • Sep 29, 2024
  • 2 min read

REYKJAVIK, Iceland -- 29 Sept, 2024 -- Akthelia Pharmaceuticals announces that Prof. dr. Nicole Blijlevens has joined the company's Scientific Advisory Board.


Prof. dr. Nicole Blijlevens is a leading expert in gastrointestinal mucositis. She is a professor and head of Hematology at Radboudumc, with over two decades of experience. Her work focuses on reducing cancer therapy side effects, especially gastrointestinal mucositis, through personalized care. She is involved in international groups like the Mucositis Study Group of MASCC and has published extensively. In 2024, she was honored with the Officer in the Order of Orange-Nassau for her contributions.


Her academic journey includes an MD and PhD in internal medicine, with a subspecialty in Hematology. She joined Radboudumc as a staff member in Hematology in 2002, becoming department head and professor in 2011. Over the years, she has held various leadership roles, including medical director of the Hemophilia Treatment Center since 2014 and chair of the hematology department. Her extensive experience, spanning over two decades by 2025, underscores her deep involvement in the field.


Prof. Blijlevens' research is primarily focuses on personalized supportive care to reduce the side effects of cancer therapy for patients with hematological diseases. Gastrointestinal mucositis, a significant complication of chemotherapy and radiotherapy, is a central theme in her work. This condition involves inflammation of the digestive system's mucous membranes, leading to symptoms like diarrhea and abdominal pain, and is linked to systemic inflammation and microbiome disturbances. Her research aims to develop strategies to mitigate these effects, improving patient outcomes through personalized approaches.


Her involvement in international committees further highlights her expertise. She is a certified clinical inspector for the JACIE SCT accreditation program and a member of the Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation (EBMT), as well as the Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC), ICHS, and ECIL. Notably, her membership in the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer (MASCC) and the Oral Care Study Group of MASCC/ISOO directly aligns with her focus on gastrointestinal mucositis..





 

ABOUT AKTHELIA PHARMACEUTICALS


Akthelia Pharmaceuticals is a pioneering biopharmaceutical company, focusing on therapeutics that target mucosal barrier injury and epithelial integrity, via a novel biology-driven immunotherapeutic strategy that upregulates epithelial surfaces.


Akthelia's lead program is a late preclinical stage asset with potential to be a first-in-class oral therapeutic addressing the large unmet need to improve cancer care outcomes by reducing the risk of chemotherapy-induced bloodstream infections. Akthelia's platform also addresses the urgent global threat of antibiotic bacterial resistance (AMR).


 

CONTACTS

Akthelia Pharmaceuticals Grandagardi 16 101 Reykjavik Iceland

 
 
bottom of page